Efficacy of taxol in the orpk mouse model of polycystic kidney disease. Pediatr Nephrol 1997 Dec;11(6):728-33
Date
01/23/1998Pubmed ID
9438653DOI
10.1007/s004670050376Scopus ID
2-s2.0-0030710548 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
Polycystic kidney disease (PKD) a is common disease in the human population that can lead to renal failure and death. Taxol has recently been reported to be of therapeutic benefit in the cpk mouse model of PKD. To determine whether these results also apply to other models of PKD, we studied the effects of taxol treatment on the development of renal cysts and biliary hyperplasia/dysplasia/fibrosis in the orpk mouse mutant, a unique murine model for human autosomal recessive PKD. We report no significant differences between the treatment and control groups with respect to weight gain, survival, urine to serum osmolality ratio, and serum concentration of liver enzymes. Moreover, renal cystic development was not affected by taxol treatment in the orpk mutant animals. This was confirmed by lectin staining and morphometric analysis of the renal cysts, which indicated no significant differences between treatment groups. Therefore, while taxol has a positive effect on the cystic kidney disease in cpk mutant mice, this effect is not applicable to all forms of PKD.
Author List
Sommardahl CS, Woychik RP, Sweeney WE, Avner ED, Wilkinson JEAuthor
Ellis D. Avner MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgingAlkaline Phosphatase
Animals
Antineoplastic Agents, Phytogenic
ErbB Receptors
Genes
Immunohistochemistry
Kidney
Liver
Mice
Mutation
Osmolar Concentration
Paclitaxel
Polycystic Kidney Diseases
